

CLAIMS

We claim:

1. An isolated nucleic acid molecule encoding a *Herpesviridae* thymidine kinase enzyme comprising at least one mutation in the Q substrate binding domain, wherein said mutation increases a biological activity of said thymidine kinase, as compared to unmutated thymidine kinase.

2. An isolated nucleic acid molecule a *Herpesviridae* thymidine kinase enzyme comprising at least three mutations, at least two of said mutations encoding amino acid substitutions that are located one, two or three amino acids toward the N-terminus from a DRH nucleoside binding site, and at least one of said mutations encoding an amino acid substitution that is located four or five amino acids toward the C-terminus from a DRH nucleoside binding site, wherein said mutations increase a biological activity of said thymidine kinase, as compared to unmutated thymidine kinase.

3. The isolated nucleic acid molecule of claim 1, further comprising at least one mutation that is an amino acid substitution within a DRH nucleoside binding site.

4. The isolated nucleic acid molecule of claim 1, further comprising at least one mutation that is an amino acid substitution located 4, 5 or 6 amino acids toward the C-terminus from a DRH nucleoside binding site.

5. The isolated nucleic acid molecule encoding a thymidine kinase enzyme according to claim 1 further comprising at least one mutation that encodes an amino acid substitution located from 1 to 7 amino acids toward the N-terminus from the DRH nucleoside binding site.

6. The isolated nucleic acid molecule encoding a thymidine kinase enzyme according to any one of claims 1-5, wherein said thymidine kinase is selected from

the group consisting of Herpes Simplex Virus Type 1 thymidine kinase and Herpes Simplex Virus Type 2 thymidine kinase.

7. The isolated nucleic acid molecule encoding a thymidine kinase enzyme according to claims 1 or 2 wherein said enzyme is truncated or contains an in-frame deletion.

8. The isolated nucleic acid molecule encoding a thymidine kinase enzyme according to claims 1 or 2 wherein said thymidine kinase enzyme is capable of phosphorylating a nucleoside analogue at least one-fold over the phosphorylation of the nucleoside analogue by a wild-type thymidine kinase enzyme.

9. The isolated nucleic acid molecule according to claim 8 wherein said nucleoside analogue is selected from the group consisting of ganciclovir, acyclovir, trifluorothymidine, 1-[2-deoxy, 2-fluoro, beta-D-arabino furanosyl]-5-iodouracil, ara-A, araT 1-beta-D-arabinofuranoxyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, idoxuridine, AZT, AIU, dideoxycytidine and AraC.

10. The isolated nucleic acid molecule encoding a thymidine kinase enzyme according to claims 1 or 2 wherein said thymidine kinase enzyme is capable of phosphorylating a nucleoside analogue, and wherein

$$z < \left[\frac{(\text{TK}_m \text{NA}_p)/(\text{TK}_m \text{T}_p)}{(\text{TK}_{wt} \text{NA}_p)/(\text{TK}_{wt} \text{T}_p)} \right]$$

wherein $\text{TK}_m \text{NA}_p$ is the rate of phosphorylation of a nucleoside analogue by a thymidine kinase mutant, $\text{TK}_m \text{T}_p$ is the rate of phosphorylation of thymidine by a thymidine kinase mutant, $\text{TK}_{wt} \text{NA}_p$ is the rate of phosphorylation of a nucleoside analogue by an unmutated thymidine kinase enzyme, $\text{TK}_{wt} \text{T}_p$ is the rate of phosphorylation of a thymidine kinase enzyme by an unmutated thymidine kinase enzyme, and z is selected from the group consisting of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5.

11. The isolated nucleic acid molecule according to claim 10 wherein said nucleoside analogue is selected from the group consisting of ganciclovir, acyclovir, trifluorothymidine, 1-[2-deoxy, 2-fluoro, beta-D-arabino furanosyl]-5-iodouracil, ara-A, araT 1-beta-D-arabinofuranoxyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, idoxuridine, AZT, AIU, dideoxycytidine and AraC.

12. An expression vector, comprising a promoter operably linked to a nucleic acid molecule according to any one of claims 1 to 11.

13. The expression vector according to claim 12 wherein said promoter is selected from the group consisting of MoMLV LTR, Cytomegalovirus Immediate Early Promoter, and Cytomegalovirus Immediate Late Promoter.

14. The expression vector according to claim 13 wherein said promoter is a tissue-specific promoter.

15. The expression vector according to claim 14 wherein said tissue-specific promoter is selected from the group consisting of the tyrosine hydroxylase promoter, adipocyte P2 promoter, PEPCK promoter, α fetoprotein promoter, whey acidic promoter, and casein promoter.

16. An isolated nucleic acid molecule encoding a fusion protein comprising a guanylate kinase moiety and a thymidine kinase moiety, wherein said fusion protein possesses a biological activity of guanylate kinase and a biological activity of thymidine kinase, wherein said thymidine kinase moiety is either a *Herpesviridae* thymidine kinase or a mutant *Herpesviridae* thymidine kinase that possesses an increased biological activity, compared with unmutated thymidine kinase.

17. The isolated nucleic acid molecule according to claim 16, wherein at least one of said guanylate kinase moiety and said thymidine kinase moiety is truncated.

18. The isolated nucleic acid molecule according to claim 16, wherein said guanylate kinase moiety is a mammalian guanylate kinase.

19. The isolated nucleic acid molecule according to claim 18, wherein said mammalian guanylate kinase moiety is a murine guanylate kinase or a human guanylate kinase.

20. The isolated nucleic acid molecule according to claim 16, wherein said mutant thymidine kinase is an enzyme comprising one or more mutations, at least one of said mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site.

21. The isolated nucleic acid molecule according to claim 16, wherein said mutant thymidine kinase is an enzyme comprising one or more mutations, at least one of said mutations being an amino acid substitution within a DRH nucleoside binding site.

22. The isolated nucleic acid molecule according to claim 16, wherein said mutant thymidine kinase is an enzyme comprising at least three mutations, at least two of said mutations encoding amino acid substitutions that are located one, two or three amino acids toward the N-terminus from a DRH nucleoside binding site, and at least one of said mutations encoding an amino acid substitution that is located four or five amino acids toward the C-terminus from a DRH nucleoside binding site.

23. The isolated nucleic acid molecule according to claim 20, wherein said mutant thymidine kinase is an enzyme comprising at least one mutation in the Q substrate binding domain.

24. The isolated nucleic acid molecule according to claim 16, wherein said thymidine kinase is selected from the group consisting of Herpes Simplex Virus Type 1 thymidine kinase and Herpes Simplex Virus Type 2 thymidine kinase.

25. An expression vector comprising the isolated nucleic acid molecule of claim 16.

26. The expression vector of claim 25 further comprising a promoter operably linked to said nucleic acid molecule.

27. A viral vector capable of directing the expression of a nucleic acid molecule according to any one of claims 1-11 and 16.

28. The viral vector according to claim 27 wherein said vector is selected from the group consisting of herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors.

29. Host cells carrying a vector according to claim 27.

30. The host cells according to claim 29 wherein said cells are selected from the group consisting of human cells, dog cells, monkey cells, rat cells, and mouse cells.

31. An isolated *Herpesviridae* thymidine kinase enzyme comprising at least three mutations, at least two of said mutations encoding amino acid substitutions that are located one, two or three amino acids toward the N-terminus from a DRH nucleoside binding site, and at least one of said mutations encoding an amino acid substitution that is located four or five amino acids toward the C-terminus from a DRH nucleoside binding site, wherein said mutations increase a biological activity of said thymidine kinase, as compared to unmutated thymidine kinase.

09133463 "104408

38. The isolated *Herpesviridae* thymidine kinase enzyme according to claims 31 or 32 wherein said thymidine kinase enzyme is capable of phosphorylating a nucleoside analogue at least one-fold over the phosphorylation of the nucleoside analogue by a wild-type thymidine kinase enzyme.

39. The isolated *Herpesviridae* thymidine kinase enzyme according to claim 38 wherein said nucleoside analogue is selected from the group consisting of ganciclovir, acyclovir, trifluorothymidine, 1-[2-deoxy, 2-fluoro, beta-D-arabino furanosyl]-5-iodouracil, ara-A, araT 1-beta-D-arabinofuranoxyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, idoxuridine, AZT, AIU, dideoxycytidine and AraC.

40. The *Herpesviridae* thymidine kinase enzyme according to claims 31 or 32 wherein said thymidine kinase enzyme is capable of phosphorylating a nucleoside analogue, and wherein

$$z < \left[\frac{(\text{TK}_m \text{NA}_p)/(\text{TK}_m \text{T}_p)}{(\text{TK}_{wt} \text{NA}_p)/(\text{TK}_{wt} \text{T}_p)} \right]$$

wherein $\text{TK}_m \text{NA}_p$ is the rate of phosphorylation of a nucleoside analogue by a thymidine kinase mutant, $\text{TK}_m \text{T}_p$ is the rate of phosphorylation of thymidine by a thymidine kinase mutant, $\text{TK}_{wt} \text{NA}_p$ is the rate of phosphorylation of a nucleoside analogue by an unmutated thymidine kinase enzyme, $\text{TK}_{wt} \text{T}_p$ is the rate of phosphorylation of a thymidine kinase enzyme by an unmutated thymidine kinase enzyme, and z is selected from the group consisting of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5.

41. The *Herpesviridae* thymidine kinase enzyme according to claim 40 wherein said nucleoside analogue is selected from the group consisting of ganciclovir, acyclovir, trifluorothymidine, 1-[2-deoxy, 2-fluoro, beta-D-arabino furanosyl]-5-iodouracil, ara-A, araT 1-beta-D-arabinofuranoxyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, idoxuridine, AZT, AIU, dideoxycytidine and AraC.

42. A fusion protein comprising a guanylate kinase moiety and a thymidine kinase moiety, wherein said fusion protein possesses a biological activity of said guanylate kinase and a biological activity of said thymidine kinase, wherein said thymidine kinase moiety is either a *Herpesviridae* thymidine kinase or a mutant *Herpesviridae*

thymidine kinase that possesses an increased biological activity, compared with unmutated thymidine kinase.

43. The fusion protein according to claim 42, wherein at least one of said guanylate kinase moiety and said thymidine kinase moiety is truncated.

44. The fusion protein according to claim 42, wherein said guanylate kinase moiety is a mammalian guanylate kinase.

45. The isolated nucleic acid molecule according to claim 44, wherein said mammalian guanylate kinase moiety is a murine guanylate kinase or a human guanylate kinase.

46. The fusion protein according to claim 42, wherein said mutant thymidine kinase is an enzyme comprising one or more mutations, at least one of said mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site.

47. The fusion protein according to claim 42, wherein said mutant thymidine kinase is an enzyme comprising one or more mutations, at least one of said mutations being an amino acid substitution within a DRH nucleoside binding site.

48. The fusion protein according to claim 42, wherein said mutant thymidine kinase is an enzyme comprising at least three mutations, at least two of said mutations encoding amino acid substitutions that are located one, two or three amino acids toward the N-terminus from a DRH nucleoside binding site, and at least one of said mutations encoding an amino acid substitution that is located four or five amino acids toward the C-terminus from a DRH nucleoside binding site.

49. The fusion protein according to claim 46, wherein said mutant thymidine kinase is an enzyme comprising at least one mutation in the Q substrate binding domain.

50. The fusion protein according to claim 42, wherein said thymidine kinase is selected from the group consisting of Herpes Simplex Virus Type 1 thymidine kinase and Herpes Simplex Virus Type 2 thymidine kinase.

51. A method of inhibiting a pathogenic agent in a warm-blooded animal, comprising administering to a warm-blooded animal a vector according to claim 27, such that said pathogenic agent is inhibited.

52. The method according to claim 51 wherein said vector is administered *in vivo*.

53. The method according to claim 51 wherein said pathogenic agent is selected from the group consisting of viruses, bacteria and parasites.

54. The method according to claim 51 wherein said pathogenic agent is a tumor cell.

55. The method according to claim 51 wherein said pathogenic agent is an autoreactive immune cell.

56. The method according to any one of claims 51 to 55, further comprising the step of administering a nucleoside analogue.

57. The method according to claim 56 wherein said nucleoside analogue is selected from the group consisting of ganciclovir, acyclovir, trifluorothymidine, 1-[2-deoxy, 2-fluoro, beta-D-arabino furanosyl]-5-iodouracil, ara-A, araT 1-beta-D-arabinofuranoxyl

thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, idoxuridine, AZT, AIU, dideoxycytidine and AraC.

58. A pharmaceutical composition, comprising a vector according to claim 27, and a pharmaceutically acceptable carrier or diluent.

59. A pharmaceutical composition, comprising a host cell according to claim 29, along with a pharmaceutically acceptable carrier or diluent.

60. A method for monitoring the progress of gene therapy in a subject who has received a vector comprising a nucleic acid molecule of either claim 1 or claim 2 that encodes a *Herpesviridae* thymidine kinase enzyme and a radiolabeled anti-viral drug that is a substrate for said thymidine kinase, comprising the step of scanning said subject for the presence of said radiolabeled anti-viral drug.

36424263

Add B11